These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1234 related items for PubMed ID: 27916269

  • 1. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [Abstract] [Full Text] [Related]

  • 2. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, Bordi G, Vitagliano A, Saccardi C, Skof E.
    Radiol Oncol; 2018 Sep 11; 52(3):307-319. PubMed ID: 30210049
    [Abstract] [Full Text] [Related]

  • 3. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A, Mogensen O, dePont Christensen R, Jensen PT.
    Int J Gynecol Cancer; 2014 Oct 11; 24(8):1420-8. PubMed ID: 25180461
    [Abstract] [Full Text] [Related]

  • 4. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y, Lee M, Kim HS, Chung HH, Song YS.
    Medicine (Baltimore); 2016 Sep 11; 95(36):e4797. PubMed ID: 27603388
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.
    Fagö-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, Mosgaard BJ, Ottosen C, Soegaard CH, Soegaard-Andersen E, Hoegdall C.
    Gynecol Oncol; 2014 Feb 11; 132(2):292-8. PubMed ID: 24321400
    [Abstract] [Full Text] [Related]

  • 7. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 May 11; 47(5):355-60. PubMed ID: 22883524
    [Abstract] [Full Text] [Related]

  • 8. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C, Yao K, Li L, Yi T, Zhao X.
    Arch Gynecol Obstet; 2016 Jan 11; 293(1):163-168. PubMed ID: 26198168
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
    Gadducci A, Cosio S, Zizioli V, Notaro S, Tana R, Panattoni A, Sartori E.
    Int J Gynecol Cancer; 2017 Jan 11; 27(1):28-36. PubMed ID: 27870700
    [Abstract] [Full Text] [Related]

  • 13. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS.
    Gynecol Oncol; 2013 Apr 11; 129(1):63-8. PubMed ID: 23337490
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y, Grant MS, Zhang X, Paraghamian SE, Tan X, Clark LH.
    J Minim Invasive Gynecol; 2021 Jun 11; 28(6):1237-1243. PubMed ID: 33248314
    [Abstract] [Full Text] [Related]

  • 17. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
    Pepin K, Bregar A, Davis M, Melamed A, Hinchcliff E, Gockley A, Horowitz N, Del Carmen MG.
    Gynecol Oncol; 2017 Dec 11; 147(3):612-616. PubMed ID: 28988028
    [Abstract] [Full Text] [Related]

  • 18. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
    Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS.
    Gynecol Oncol; 2013 Apr 11; 129(1):69-73. PubMed ID: 23375727
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G.
    Eur J Cancer; 2016 May 11; 59():22-33. PubMed ID: 26998845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.